- Home
- ZH vs ITOS Comparison
ZH vs ITOS Comparison
Compare ZH & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- ITOS
- Stock Information
- Founded
- ZH 2011
- ITOS 2011
- Country
- ZH China
- ITOS United States
- Employees
- ZH N/A
- ITOS N/A
- Industry
- ZH Business Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZH Consumer Discretionary
- ITOS Health Care
- Exchange
- ZH Nasdaq
- ITOS Nasdaq
- Market Cap
- ZH 304.3M
- ITOS 280.6M
- IPO Year
- ZH 2021
- ITOS 2020
- Fundamental
- Price
- ZH $3.35
- ITOS $8.00
- Analyst Decision
- ZH Strong Buy
- ITOS Strong Buy
- Analyst Count
- ZH 2
- ITOS 3
- Target Price
- ZH $5.65
- ITOS $21.33
- AVG Volume (30 Days)
- ZH 189.0K
- ITOS 470.7K
- Earning Date
- ZH 11-26-2024
- ITOS 03-05-2025
- Dividend Yield
- ZH N/A
- ITOS N/A
- EPS Growth
- ZH N/A
- ITOS N/A
- EPS
- ZH N/A
- ITOS N/A
- Revenue
- ZH $552,853,374.00
- ITOS $35,000,000.00
- Revenue This Year
- ZH N/A
- ITOS $271.18
- Revenue Next Year
- ZH $8.26
- ITOS N/A
- P/E Ratio
- ZH N/A
- ITOS N/A
- Revenue Growth
- ZH N/A
- ITOS N/A
- 52 Week Low
- ZH $2.55
- ITOS $7.09
- 52 Week High
- ZH $5.28
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- ZH 41.44
- ITOS 53.50
- Support Level
- ZH $3.19
- ITOS $7.63
- Resistance Level
- ZH $3.62
- ITOS $8.09
- Average True Range (ATR)
- ZH 0.16
- ITOS 0.30
- MACD
- ZH -0.02
- ITOS 0.06
- Stochastic Oscillator
- ZH 23.85
- ITOS 74.11
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.